Pharmacotherapy in Tobacco Cessation: A Narrative Review

A chronic, recurring illness, known as nicotine addiction and dependence, is defined by a person's dependence on the substance up to the extent that their normal day-to-day activities are compromised in the absence of the substance. This paper will highlight first-line smoking cessation treatments, such as nicotine replacement therapy (NRT), bupropion, and varenicline, and second-line medications, such as clonidine, nortriptyline, anxiolytics, mecamylamine, naltrexone, and NicVAX (Nabi Biopharmaceuticals, Rockville, MD, USA). NRT offers many options for nicotine delivery methods, comprising nicotine gum, rapid-release gum, lozenges, transdermal patches, high-dose nicotine patches, oral inhalers, nasal sprays, electronic nicotine delivery systems (ENDS), and sublingual tablets. Pharmacotherapies for quitting tobacco should lessen withdrawal symptoms and stop nicotine's reinforcing effects without having too many side effects.

[1]  Alan D. Lopez,et al.  Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action , 2022, Tobacco Control.

[2]  Amanda M. Singrey,et al.  The current state of tobacco cessation treatment , 2021, Cleveland Clinic Journal of Medicine.

[3]  J. Hovis,et al.  Effects of Nicotine Gum Administration on Vision (ENIGMA-Vis): Study Protocol of a Double-Blind, Randomized, and Controlled Clinical Trial , 2020, Frontiers in Human Neuroscience.

[4]  L. de Graaf.  Nortriptyline , 2020, Nursing.

[5]  Shruti Sinha,et al.  Nicotine replacement therapy: A friend or foe , 2020, Journal of family medicine and primary care.

[6]  K. Kingsley,et al.  Harmful chemicals emitted from electronic cigarettes and potential deleterious effects in the oral cavity , 2020, Tobacco induced diseases.

[7]  Jian Kang,et al.  A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of a Nicotine Mint Lozenge (2 and 4 mg) in Smoking Cessation , 2020, Journal of addiction medicine.

[8]  G. Roviello,et al.  Electronic nicotine delivery systems (ENDS): not still ready to put on END , 2020, Journal of thoracic disease.

[9]  Louis A. Pagliaro,et al.  Naltrexone , 2020, Reactions Weekly.

[10]  M. Nazir,et al.  Global Prevalence of Tobacco Use in Adolescents and Its Adverse Oral Health Consequences , 2019, Open access Macedonian journal of medical sciences.

[11]  Y. Nishimura,et al.  Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials , 2019, Therapeutic advances in respiratory disease.

[12]  N. Rigotti,et al.  2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2018, Journal of the American College of Cardiology.

[13]  M. Berk,et al.  Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking , 2018, Pharmacotherapy.

[14]  L. McMahon,et al.  The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice , 2017, Psychopharmacology.

[15]  N. Benowitz,et al.  Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial , 2016, The Lancet.

[16]  Umesh Wadgave,et al.  Nicotine Replacement Therapy: An Overview. , 2016, International journal of health sciences.

[17]  D. Tracy,et al.  Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant , 2016, Therapeutic advances in psychopharmacology.

[18]  O. V. van Schayck,et al.  Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. , 2014, Addiction.

[19]  C. Moyses,et al.  Evaluation of a Novel Nicotine Inhaler Device: Part 2—Effect on Craving and Smoking Urges , 2014, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[20]  Laurie Brokowski,et al.  High-dose transdermal nicotine replacement for tobacco cessation. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[21]  S. David,et al.  Systematic review and meta-analysis of opioid antagonists for smoking cessation , 2014, BMJ Open.

[22]  I. Berlin,et al.  Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice , 2014, British journal of clinical pharmacology.

[23]  Raj Kumar,et al.  Smoking cessation programs and other preventive strategies for chronic obstructive pulmonary disease. , 2012, The Journal of the Association of Physicians of India.

[24]  D. Hatsukami,et al.  Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[25]  T. Perneger,et al.  Nicotine gum treatment before smoking cessation: a randomized trial. , 2009, Archives of internal medicine.

[26]  S. Shiffman,et al.  Rapid absorption of nicotine from new nicotine gum formulations , 2009, Pharmacology Biochemistry and Behavior.

[27]  S. Hall,et al.  Therapeutic Drug Monitoring of Nortriptyline in Smoking Cessation: A Multistudy Analysis , 2008, Clinical pharmacology and therapeutics.

[28]  D. Schroeder,et al.  Nicotine lozenges for the treatment of smokeless tobacco use. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[29]  S. Tonstad,et al.  Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. , 2006, JAMA.

[30]  M. Stitzer,et al.  Pharmacotherapy for Nicotine Dependence 1 , 2005, CA: a cancer journal for clinicians.

[31]  M. Zeegers,et al.  Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. , 2005, Addiction.

[32]  E. Králíková,et al.  ABC of smoking cessation: Nicotine replacement therapy , 2004, BMJ : British Medical Journal.

[33]  G. Hobbs,et al.  A comparison of a nicotine sublingual tablet and placebo for smoking cessation. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[34]  L. Stead,et al.  Anxiolytics for smoking cessation. , 2000, The Cochrane database of systematic reviews.

[35]  S. Mohiuddin,et al.  Randomized, Controlled Trial of Transdermal Clonidine for Smoking Cessation , 1993, The Annals of pharmacotherapy.

[36]  R. Rawson,et al.  Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. , 1984, NIDA research monograph.

[37]  S. Goldberg,et al.  Control of behavior by intravenous nicotine injections in laboratory animals , 1983, Pharmacology Biochemistry and Behavior.

[38]  S. Goldberg,et al.  Control of behavior by intravenous nicotine injections in human subjects , 1983, Pharmacology Biochemistry and Behavior.

[39]  C. Sumana,et al.  Nicotine replacement therapy: A review , 2018 .

[40]  G. Casazza,et al.  Glucocorticosteroids for people with alcoholic hepatitis (Protocol) , 2016 .

[41]  R. Jiloha.  Pharmacotherapy of smoking cessation , 2014, Indian journal of psychiatry.

[42]  P. Tønnesen,et al.  Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. , 2006, Chest.